A novel RYR2 loss-of-function mutation (I4855M) is associated with left ventricular non-compaction and atypical catecholaminergic polymorphic ventricular tachycardia

J Electrocardiol. 2017 Mar-Apr;50(2):227-233. doi: 10.1016/j.jelectrocard.2016.09.006. Epub 2016 Sep 8.

Abstract

Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an ion channelopathy usually caused by gain-of-function mutations ryanodine receptor type-2 (RyR2). Left ventricular non-compaction (LVNC) is an often genetic cardiomyopathy. A rare LVNC-CPVT overlap syndrome may be caused by exon 3 deletion in RyR2. We sought to characterize the phenotypic spectrum and molecular basis of a novel RyR2 mutation identified in a family with both conditions.

Methods: Several members of an affected family underwent clinical and genetic assessments. A homology model of the RyR2 pore-region was generated to predict the location and potential impact of their RyR2 mutation. Ca2+-release assays were performed to characterize the functional impact of the RyR2 mutant expressed in HEK293 cells.

Results: A multigenerational family presented with a history of sudden death and a phenotype of atypical CPVT and LVNC. Genetic testing revealed a RYR2 mutation (I4855M) in two affected individuals. A homology model of the RyR2 pore-region showed that the I4855M mutant reside is located in the highly conserved 'inner vestibule', a water-filled cavity. I4855M may interfere with Ca2+ permeation and affect interactions between RyR2 pore subunits, and is thus predicted in silico to be damaging. Expression and functional studies in HEK293 cells revealed that I4855M inhibited caffeine-induced Ca2+ release and exerted a dominant-negative impact on wild type RyR2.

Conclusions: This study identifies a potentially lethal overlapping syndrome of LVNC and atypical CPVT related to a novel RYR2 variant. Structural and functional studies suggest that this is a loss-of-function mutation, which exerts a dominant-negative effect on wild type RyR2.

Keywords: Arrhythmia; Catecholaminergic polymorphic ventricular tachycardia; Left ventricular non-compaction; Ryanodine receptor-2; Sudden unexpected death.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Female
  • Genetic Association Studies
  • Genetic Markers / genetics
  • Genetic Predisposition to Disease / genetics*
  • Genetic Testing
  • Heart Defects, Congenital / complications
  • Heart Defects, Congenital / diagnosis
  • Heart Defects, Congenital / genetics*
  • Humans
  • Male
  • Mutation / genetics
  • Polymorphism, Single Nucleotide / genetics*
  • Ryanodine Receptor Calcium Release Channel / genetics*
  • Tachycardia, Ventricular / complications
  • Tachycardia, Ventricular / diagnosis*
  • Tachycardia, Ventricular / genetics*
  • Young Adult

Substances

  • Genetic Markers
  • RyR2 protein, human
  • Ryanodine Receptor Calcium Release Channel

Supplementary concepts

  • Noncompaction of Left Ventricular Myocardium with Congenital Heart Defects
  • Polymorphic catecholergic ventricular tachycardia

Grants and funding